Scott+Scott Attorneys at Law LLP Investigates Pfizer, Inc.'s Directors and Officers for Breach of Fiduciary Duties

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Pfizer, Inc. ("Pfizer" or "Company") (NYSE: PFE) breached their fiduciary duties to PFE and its shareholders. If you are a Pfizer shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or jpettigrew@scott-scott.com .

Scott+Scott is investigating whether Pfizer's board of directors or senior management failed to manage Pfizer in an acceptable manner, in breach of their fiduciary duties to Pfizer, and whether Pfizer has suffered damages as a result.

On November 5, 2020, Pfizer disclosed that it had received an inquiry from the U.S. Securities and Exchange Commission's ("SEC") foreign-bribery unit, as well as informal requests for information from the SEC and the Department of Justice regarding the Company's operations in China and Russia.

What You Can Do

If you are a Pfizer shareholder, you may have legal claims against Pfizer's directors and officers. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at 844-818-6982 or jpettigrew@scott-scott.com .

About Scott+Scott

Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, and Ohio.

Attorney Advertising

Joe Pettigrew
Scott+Scott Attorneys at Law LLP
230 Park Avenue, 17th Floor, New York, NY 10169
844-818-6982
jpettigrew@scott-scott.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs for Investors in 2026

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies and the pharma market as a whole. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the... Keep Reading...
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2026... Keep Reading...
InMed Pharmaceuticals Amends Preferred Investment Options

InMed Pharmaceuticals Amends Preferred Investment Options

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into amending agreements in respect of... Keep Reading...
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

5 Best-performing Canadian Pharma Stocks in 2026

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover and develop major innovations amid an increasingly competitive global landscape. Rising technologies such as artificial intelligence are... Keep Reading...
Seegnal

Seegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx as Investor Relations Advisor

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Company"), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced the formation of a dedicated Strategic Commercialization Team led by its Chief Executive Officer, and the... Keep Reading...
Dollar bills, pink and white pills in blister packs, and a nasal spray on a blue background.

Blackstone Raises Record US$6.3 Billion for Largest Life Sciences Fund

Blackstone (NYSE:BX) has raised US$6.3 billion for its latest life sciences fund, the largest private vehicle dedicated to the sector.The fund, Blackstone Life Sciences VI (BXLS VI), was oversubscribed and closed at its hard cap, about 40 percent larger than its predecessor, which raised US$4.6... Keep Reading...

Interactive Chart

Latest Press Releases

Related News